VBI Vaccines — Corporate Update (June 2019)
12 slides from VBI Vaccines's corporate update, Jun 17, 2019
Slide 1: Sci-B-Vac PROTECT Phase III Top-Line Data
% S 7) Sci-B-Vac® PROTECT Phase III Top-Line Data NASDAQ: VBIV JUNE 17 2019
Slide 2: Forward-Looking Statements
Dee ee Forward-Looking Statements Certain statements in this presentation that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are forward-looking inf
Slide 3: Sci-B-Vac: Two Ongoing Phase III Studies to Support Approval in U.S., Europe, and Canada
Sci-B-Vac®: Two Ongoing Phase III Studies to Support Approval in U.S., Europe, and Canada Phase Ill Study PROTECT 2-arm safety and immunogenicity study CONSTANT 4-arm lot-to-lot consistency study Nsize Control Vaccine Primary Endpoint(s) Secondary Endpoint(s) Expected Top-Line Data Readout 1,607 Eng
Slide 4: PROTECT Study Subject Disposition
Se PROTECT Study Subject Disposition Subjects screened (n=2,472) ————|_ Screening failure (n=865, 35%) ’ Randomized (n=1,607) at 28 clinical study si Europe, and Canada f t Engerix-B (n=811) + Full Analysis Set > Sci-B-Vac (n=796) Age: Age: * 18-44 years : 154 (19%) * 18-44 years : 145 (18%) + 45-64
Slide 5: Both PROTECT Co-Primary Endpoints Successfully Met
Both PROTECT Co-Primary Endpoints Successfully Met Co-Primary Endpoints at Day 196, 4 weeks post-3" vaccination: Percent HBsAg Seroprotection 1. Non-Inferiority of seroprotection rate (SPR) al superiority, as define achieved in all subjects age 18+ ved in subjects age 45+ Diff: 14.9% Diff: 16.4% 95%
Slide 6: Kinetics of Seroprotection Rates by Age Groups
Se Kinetics of Seroprotection Rates by Age Groups All Ages (18+) } a aa% —Engerix-B —Sci-BVac Seroprotection Rate (SPR°%} 99.2% 97.5% Seroprotection Rate (SPR°%} ) 2 4 6 8 10 12 Months =Vaccinations © -Time of anaysisof co-primary endpoints NASDAQ : VBIV 6
Slide 7: Seroprotection Rates in Subgroup Populations
Seroprotection Rates in Subgroup Populations SPR of Sci-B-Vac® vs. Engerix-B® was statistically significantly higher in all key subgroup analyses of adults age 2 18 years, at Day 196, 4 weeks post-3"¢ vaccination, including: 58.3% Engerix-B® vs. 83.3% Sci-B-Vac® Diabetics SPR difference: 25.0%; 95%
Slide 8: Anti-HBsAg Titers in Subgroup Populations
Anti-HBsAg Titers in Subgroup Populations 5-8x fold higher antibody GMC is maintained for patients who received Sci-B-Vac vs. Engerix-B regardless of age, BMI, or diabetes status ee <1 | =e Anti-HBsAg (mlU/mL) 6x 8 8 All Ages 10 Al 18-39 yo. 4.4X yo. 5.9X 64x 50-59 60-69 yo. yo. mi Engeri B_ mSci-B-
Slide 9: Summary of Safety Data (1)
ee Summary of Safety Data (1) OVERALL: * No safety signals observed in PROTECT * — Sci-B-Vac safety profile consistent with previous studies and post- marketing use (Israel) * — High rate of completion of vaccinations, 96.8% and 95.2% for Engerix-B and Sci-B-Vac, respectively * Low rate of vaccine d
Slide 10: Summary of Safety Data (2)
ee Summary of Safety Data (2) Serious Adverse Events (SAEs) Unsolicited Adverse Events (AEs) Engerix-B® ‘Sci-B-Vac® Engerix-B® ‘Sci-B-Vac® Total SAEs (63) 21 (2.6%) 32 (4.0%) 1+ AEs reported (% of sub.) 54.5% 52.5% SAEs occurring in 2 2 subjects: AEs reported by 2 1% of subjects: Headache 8.3% 8.5%
Slide 11: Conclusions & Next Steps
Conclusions & Next Steps * PROTECT top-line data showed Sci-B-Vac® to have higher rates of protection in all adults, when compared with Engerix-B®, with statistical and clinical superiority in adults age 45 years and older * This data reaffirms the clean safety profile of the vaccine, with no safety
Slide 12: VBI Vaccines Inc. contact details
VBI Vaccines Inc. 222 Third Street, Suite 2241 Cambridge, MA 02142 (617) 830-3031 [email protected]